entertainment -WSS

entertainment

author：knowledge 2025-10-02 20:06:41 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Female surgeons have lower rates of long

WSS

A fraught question for the kids of Alzheimer’s: Is it coming for us?

FDA official pushes for dedicated emerging pathogens team

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

STAT Readout Newsletter: Today in biotech, life science news

Providers still hesitate to prescribe buprenorphine, study finds

Cancer cells are shown to suck energy source from immune cells

knowledge

entertainment

explore

Affirmative action in medical school literally saved lives

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Cancer drug shortages should be causing more outrage

Akero's treatment for NASH falls short in cirrhosis study

Drug repurposing or repositioning? The language matters

Takeaways from AdvaMed, the largest medical devices conference

Medicare details structure of new drug price negotiation program

Humana CEO Bruce Broussard to step down in 2024

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

7 of the most gruesome medical devices in history

entertainment

White House launches permanent pandemic office

Eight reasons why you should get an updated Covid vaccine

As Taiwan prepares for anti

As Taiwan prepares for anti

Caitlin Bernard's story shows physicians can't shy from advocacy

Takeaways from AdvaMed, the largest medical devices conference

leisure time

hotspot

focus

hotspot